Moleculin Biotech announces new Annamycin collaboration in brain tumors

Moleculin Biotech (MBRX) announced it has entered into a research and material transfer agreement with CIC biomaGUNE, a non-profit research organization created to promote scientific research and technological innovation at the highest levels in the Basque Country, Spain, for investigator-initiated preclinical research evaluating Annamycin for the treatment of glioblastoma multiforme, GBM, a form of brain cancer. Under the terms of the agreement Moleculin will supply Annamycin and Jesus Ruiz-Cabello, Principal Investigator at CIC biomaGUNE will conduct the planned preclinical research. The studies covered under this agreement will evaluate tumor progression following intra-arterial delivery of liposomal Annamycin and Free-Annamycin as compared to Doxil and Free-doxorubicin in mouse models.